MedTrace Logo

Developing Objective Measures of Levodopa Induced Dyskinesia: (Study 1)

NCT00467597 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 36

Last updated 2014-11-26

Study results available
· View outcomes & findings →

Summary

The ultimate goal of this proposal is to reduce dyskinesia in Parkinson's Disease (PD) patients. Dyskinesias are abnormal movements, often caused by the standard treatment for PD symptoms, levodopa. In this study, we will test if biochemical devices are equal to the clinical rating system in measuring dyskinesias.

Conditions

Interventions

DRUG

Levodopa (delivered intravenously)

IV Levodopa is given from 09:00 to 11:00 am during the testing phase of the study. The IV Levodopa allows the researchers to watch one full "on" and "off" levodopa cycle while in the inpatient unit.

Sponsors & Collaborators

Principal Investigators

  • Kathryn Anne Chung, MD · VA Medical Center, Portland

Eligibility

Min Age
21 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2006-04-30
Primary Completion
2008-08-31
Completion
2013-10-31

Countries

  • United States

Study Locations

More Related Trials

Entities

Diseases
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00467597 on ClinicalTrials.gov